Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment

K-REx Repository

Show simple item record

dc.contributor.author Liu, Qinfang
dc.contributor.author Ma, Jingjiao
dc.contributor.author Strayer, David R.
dc.contributor.author Mitchell, William M.
dc.contributor.author Carter, William A.
dc.contributor.author Ma, Wenjun
dc.contributor.author Richt, Juergen A.
dc.date.accessioned 2014-07-02T18:45:08Z
dc.date.available 2014-07-02T18:45:08Z
dc.date.issued 2014-07-02
dc.identifier.uri http://hdl.handle.net/2097/17896
dc.description.abstract The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths in China. Because of the lack of existing immunity against H7 subtype influenza viruses in the human population and the absence of a licensed commercial vaccine, antiviral drugs are critical tools for the treatment of infection with this novel H7N9. Both M2-ion channel blockers and neuraminidase inhibitors are used as antiviral drugs for influenza infections of humans. The emerging H7N9 viruses are resistant to the M2-ion channel blockers because of a S31N mutation in the M2 protein; additionally, some H7N9 isolates have gained neuraminidase R292K substitution resulting in broad resistance to neuraminidase inhibitors. In this study we report that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro. Since Alferon N is approved for clinical use, this would allow a rapid regulatory approval process for this drug under pandemic threat. en_US
dc.language.iso en_US en_US
dc.relation.uri http://informahealthcare.com/doi/abs/10.1586/14787210.2014.870885 en_US
dc.rights Permission to archive granted by Informa Healthcare, June 5, 2014. en_US
dc.subject H7N9 en_US
dc.subject Alferon N en_US
dc.subject Neuraminidase inhibitors en_US
dc.subject Antiviral drug en_US
dc.subject Influenza en_US
dc.subject Tamiflu en_US
dc.subject Oseltamivir resistance en_US
dc.title Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment en_US
dc.type Article (author version) en_US
dc.date.published 2014 en_US
dc.citation.doi doi:10.1586/14787210.2014.870885 en_US
dc.citation.epage 169 en_US
dc.citation.issue 2 en_US
dc.citation.jtitle Expert Review of Anti-infective Therapy en_US
dc.citation.spage 165 en_US
dc.citation.volume 12 en_US
dc.contributor.authoreid wjma en_US
dc.contributor.authoreid jricht en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search K-REx


Advanced Search

Browse

My Account

Statistics








Center for the

Advancement of Digital

Scholarship

118 Hale Library

Manhattan KS 66506


(785) 532-7444

cads@k-state.edu